FierceBiotech8h
In 'surprise' termination, Genentech drops Nykode partnership for individualized cancer vaccine
Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...
BioNTech upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs upgraded BioNTech (BNTX) to Buy from Neutral with a price target of $137, up from $90. The firm upgrade the shares after ...
What Analysts Are Saying About BioNTech Stock
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...
BioNTech SE’s Strategic Shift to Immuno-Oncology with BNT327: A Promising Investment Opportunity Amidst Stable COVID-19 Forecasts
In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...